Monitoring progress towards elimination of hepatitis B and C in the EU/EEA

• Main Authors: Katherine C. Sharrock, Teymur Noori, Maria Axelsson, Maria Buti, Asuncion Diaz, Olga Fursa, Greet Hendrickx, Cary James, Irena Klavs, Marko Korenjak, Mojca Maticic, Antons Mozalevskis, Lars Peters, Rafaela Rigoni, Magdalena Rosinska, Kristi Ruutel, Eberhard Schatz, Thomas Seyler, Irene Veldhuijzen, Erika Duffell
• Format: Article in Journal/Newspaper
• Language: English
• Published: Public Library of Science (PLoS) 2022
• Subjects: Public aspects of medicine; RA1-1270; Iceland
• Online Access: https://doaj.org/article/62e7ae728ff8473ea80c0bd779000134

This paper presents data on selected indicators to show progress towards elimination goals and targets for hepatitis B and hepatitis C in the 31 countries of the European Union (EU) and European Economic Area (EEA). A monitoring system was developed by the European Centre for Disease Prevention and Control, which combined newly collected data from EU/EEA countries along with relevant data from existing sources. Data for 2017 were collected from the EU/EEA countries via an online survey. All countries provided responses. In 2017, most countries reporting data had not reached prevention targets for childhood hepatitis B vaccination and for harm reduction services targeting people who inject drugs (PWID). Four of 12 countries had met the target for proportion of people living with chronic HBV diagnosed and seven of 16 met this target for hepatitis C. Data on diagnosed cases treated were lacking for hepatitis B. Of 12 countries reporting treatment data for hepatitis B, only Iceland met the target. This first collection of data across the EU/EEA highlighted major issues with data completeness and quality and in the indicators that were used, which impairs a clear overview of progress towards the elimination of hepatitis. The available data, whilst incomplete, suggest that as of 2017, the majority of the EU/EEA countries were far from meeting most of the 2020 targets, in particular those relating to harm reduction and diagnosis. It is critical to improve the data collected in order to develop more effective services for hepatitis prevention, diagnosis, and treatment that are needed in order to meet the 2030 elimination targets.